Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the preliminary anti-tumour activity of AZD2171 (45 mg/day) in GIST patients by assessment with FDG-PET following 8 days and 4 weeks of dosing (central review of SUVmax).
Critère d'inclusion
- Metastatic Gastro-Intestinal Stromal Tumours